413 related articles for article (PubMed ID: 27541985)
1. Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats.
Xilouri M; Brekk OR; Polissidis A; Chrysanthou-Piterou M; Kloukina I; Stefanis L
Autophagy; 2016 Nov; 12(11):2230-2247. PubMed ID: 27541985
[TBL] [Abstract][Full Text] [Related]
2. The lysosomal membrane protein LAMP2A promotes autophagic flux and prevents SNCA-induced Parkinson disease-like symptoms in the Drosophila brain.
Issa AR; Sun J; Petitgas C; Mesquita A; Dulac A; Robin M; Mollereau B; Jenny A; Chérif-Zahar B; Birman S
Autophagy; 2018; 14(11):1898-1910. PubMed ID: 29989488
[TBL] [Abstract][Full Text] [Related]
3. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
[TBL] [Abstract][Full Text] [Related]
4. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Xilouri M; Brekk OR; Landeck N; Pitychoutis PM; Papasilekas T; Papadopoulou-Daifoti Z; Kirik D; Stefanis L
Brain; 2013 Jul; 136(Pt 7):2130-46. PubMed ID: 23757764
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
[TBL] [Abstract][Full Text] [Related]
6. LAMP2A as a therapeutic target in Parkinson disease.
Xilouri M; Brekk OR; Kirik D; Stefanis L
Autophagy; 2013 Dec; 9(12):2166-8. PubMed ID: 24145820
[TBL] [Abstract][Full Text] [Related]
7. 6-OHDA Induces Oxidation of F-box Protein Fbw7β by Chaperone-Mediated Autophagy in Parkinson's Model.
Wang X; Zhai H; Wang F
Mol Neurobiol; 2018 Jun; 55(6):4825-4833. PubMed ID: 28733899
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.
Martinez-Vicente M; Talloczy Z; Kaushik S; Massey AC; Mazzulli J; Mosharov EV; Hodara R; Fredenburg R; Wu DC; Follenzi A; Dauer W; Przedborski S; Ischiropoulos H; Lansbury PT; Sulzer D; Cuervo AM
J Clin Invest; 2008 Feb; 118(2):777-88. PubMed ID: 18172548
[TBL] [Abstract][Full Text] [Related]
9. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.
Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA
J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822
[TBL] [Abstract][Full Text] [Related]
10. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
11. Ataxic phenotype and neurodegeneration are triggered by the impairment of chaperone-mediated autophagy in cerebellar neurons.
Sato M; Ohta T; Morikawa Y; Konno A; Hirai H; Kurauchi Y; Hisatsune A; Katsuki H; Seki T
Neuropathol Appl Neurobiol; 2021 Feb; 47(2):198-209. PubMed ID: 32722888
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease.
Murphy KE; Gysbers AM; Abbott SK; Spiro AS; Furuta A; Cooper A; Garner B; Kabuta T; Halliday GM
Mov Disord; 2015 Oct; 30(12):1639-47. PubMed ID: 25594542
[TBL] [Abstract][Full Text] [Related]
13. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells.
Vogiatzi T; Xilouri M; Vekrellis K; Stefanis L
J Biol Chem; 2008 Aug; 283(35):23542-56. PubMed ID: 18566453
[TBL] [Abstract][Full Text] [Related]
14. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
15. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
[TBL] [Abstract][Full Text] [Related]
16. Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models.
Mavroeidi P; Arvanitaki F; Vetsi M; Becker S; Vlachakis D; Jensen PH; Stefanis L; Xilouri M
Autophagy; 2022 Sep; 18(9):2104-2133. PubMed ID: 35000546
[TBL] [Abstract][Full Text] [Related]
17. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
19. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
20. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.
Xilouri M; Vogiatzi T; Vekrellis K; Park D; Stefanis L
PLoS One; 2009; 4(5):e5515. PubMed ID: 19436756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
